<DOC>
	<DOCNO>NCT02630979</DOCNO>
	<brief_summary>The study measure degree oncology physician satisfaction outcome cytotoxic agent .</brief_summary>
	<brief_title>Oncologists Satisfaction With Outcomes Some Cytotoxic Agents</brief_title>
	<detailed_description>This prospective observational questionnaire base study measure degree satisfaction medical oncologist result expensive cytotoxic agent . The study also measure physician knowledge toxicity profile test drug , pharmaceutical perspective , method administration , adherence guideline degree bias physician prescribe drug . The tested drug trastuzumab , lapatinib , sunitinib , tor inhibitor , sorafenib , cetuximab , panitumumab , bevacizumab , erlotinib , rituximab , imatinib mesylate , gefitinib , abiraterone acetate , cabazitaxel , pertuzumab , fulvestrant , pemetrexate crizotinib . The evaluation predesigned questionnaire ( 30 question ) . The question divide four category measure four item , degree physician satisfaction drug result toxicity profile , orientation pharmaceutical perspective drug , adherence guideline degree bias pharmaceutical company complement . A predesigned questionnaire base score system categorise process data low , intermediate high score four measure topic . The data process degree satisfaction , orientation pharmaceutical perspective , adherence guideline degree bias grade low , moderate high . Subsequent recommendation cost effective analysis , physician education strict audit measure drug prescription elaborate drug . NB : The study two wave . The first wave evaluate 9 drug second wave evaluate 8 drug .</detailed_description>
	<criteria>Physicians rank senior resident professional consultant Junior resident .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>